Nucleic acid drugs

Nucleic acid drugs, also known as Oligonucleotide Therapeutics, are analogues of natural DNA or RNA, with various chemical modifications. These modifications protect the drug from being degraded by natural enzymes, provide binding to carrier proteins for transport in the body and, most importantly, give them high affinity and specificity for their intended target. Of the approximately 20,000 proteins expressed in the human body, only about 1/3 are druggable by traditional small molecule drugs. Using Oligonucleotide Therapeutics to target the messengerRNA, which contains the recipe for the proteins, opens up the possibility to target the synthesis of those proteins that cannot be targeted by traditional small molecule drugs. In most cases both small molecule drugs and Oligonucleotide Therapeutics inhibit the function or synthesis of a given protein. However, only a handful of technologies that can upregulate the synthesis or activity of proteins currently exists: The proprietary Blockmir Technology of MJJ Biotechnologies is one of them. Hence the obvious range of targets for the Blockmirs are messengerRNAs that encode those proteins that have a protective role against disease, or proteins which are being expressed in too low amount to perform their natural duties. Oligonucleotide Therapeutics have been successfully developed to treat various diseases of the central nervous system, Musculo-skeletal diseases, diseases of the liver and Kidney, diseases of the blood, and most recently is being employed to provide vaccines against cancer and viruses such as COVID-19.